Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
| Autor: | Dansky HM, Bloomfield D, Gibbons P, Liu S, Sisk CM, Tribble D, McKenney JM, Littlejohn TW 3rd, Mitchel Y |
|---|---|
| Zdroj: | American Heart Journal; Oct2011, Vol. 162 Issue 4, p708-716, 9p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect